Smith-and-Nephew SNATS is a medical devices business based in the US. Smith-and-Nephew SNATS shares (SNN) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $25.54 – an increase of 3.74% over the previous week. Smith-and-Nephew SNATS employs 18,000 staff and has a trailing 12-month revenue of around $5.6 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $25.54 |
|---|---|
| 52-week range | $23.42 - $31.42 |
| 50-day moving average | $28.87 |
| 200-day moving average | $27.41 |
| Wall St. target price | $32.55 |
| PE ratio | 35.2 |
| Dividend yield | $0.375 (3.04%) |
| Earnings per share (TTM) | $0.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $24.89 from 2024-11-15
| 1 week (2024-11-12) | 1.26% |
|---|---|
| 1 month (2024-10-18) | -15.80% |
| 3 months (2024-08-19) | -18.02% |
| 6 months (2024-05-17) | -4.60% |
| 1 year (2023-11-17) | -2.85% |
|---|---|
| 2 years (2022-11-18) | 2.47% |
| 3 years (2021-11-19) | 31.8191 |
| 5 years (2019-11-19) | 38.1819 |
Valuing Smith-and-Nephew SNATS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew SNATS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Smith-and-Nephew SNATS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Smith-and-Nephew SNATS shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Smith-and-Nephew SNATS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4089. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew SNATS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Smith-and-Nephew SNATS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.1 billion.
The EBITDA is a measure of a Smith-and-Nephew SNATS's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $5.6 billion |
|---|---|
| Operating margin TTM | 11.6% |
| Gross profit TTM | $3.7 billion |
| Return on assets TTM | 4.51% |
| Return on equity TTM | 5.84% |
| Profit margin | 5.41% |
| Book value | $5.96 |
| Market Capitalization | $10.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 107.45% of net profits
Recently Smith-and-Nephew SNATS has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew SNATS shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Smith-and-Nephew SNATS's case, that would currently equate to about $0.375 per share.
Smith-and-Nephew SNATS's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Smith-and-Nephew SNATS's most recent dividend payout was on 7 November 2024. The latest dividend was paid out to all shareholders who bought their shares by 3 October 2024 (the "ex-dividend date").
Smith-and-Nephew SNATS's shares were split on a 2499:1000 basis on 14 October 2014 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew SNATS shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Smith-and-Nephew SNATS shares which in turn could have impacted Smith-and-Nephew SNATS's share price.
Over the last 12 months, Smith-and-Nephew SNATS's shares have ranged in value from as little as $23.4238 up to $31.4167. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Smith-and-Nephew SNATS's is 0.705. This would suggest that Smith-and-Nephew SNATS's shares are less volatile than average (for this exchange).
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.